Metabolic effects of transgenic melanocyte-stimulating hormone overexpression in lean and obese mice

Eriika Savontaus, Tracy L. Breen, Andrea Kim, Lucy M. Yang, Streamson C. Chua, Jr., Sharon L. Wardlaw

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The proopiomelanocortin-derived peptide, α-MSH, inhibits feeding via melanocortin receptors in the hypothalamus and genetic defects inactivating the melanocortin system have been shown to lead to obesity in experimental animals and humans. To determine whether long-term melanocortinergic activation has significant effects on body weight and composition and insulin sensitivity, transgenic mice overexpressing N-terminal proopiomelanocortin, including α- and γ3-MSH, under the control of the cytomegalovirus-promoter were generated. The transgene was expressed in multiple tissues including the hypothalamus, in which both α-MSH and γ3-MSH levels were increased approximately 2-fold, compared with wild-type controls. Transgene homozygous mice were also crossed with obese leptin receptor-deficient db3J and obese yellow Ay mice. MSH overespression led to uniform, dose-dependent darkening of coat color. MSH overexpression reduced weight gain and adiposity and improved glucose tolerance in lean male mice. In female transgenic mice, there was no significant effect on body weight, but there was a significant decrease in insulin levels. Obesity was attenuated in obese db3Jldb3J male and female mice, but there was no improvement in glucose metabolism. In contrast, the MSH transgene improved glucose tolerance in male Ay mice. These results support the hypothesis that long-term melanocortinergic activation could serve as a potential strategy for anti-obesity and/or antidiabetic therapy.

Original languageEnglish (US)
Pages (from-to)3881-3891
Number of pages11
JournalEndocrinology
Volume145
Issue number8
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Melanocyte-Stimulating Hormones
Obese Mice
Transgenes
Pro-Opiomelanocortin
Obesity
Glucose
Transgenic Mice
Hypothalamus
Melanocortin Receptors
Body Weight
Melanocortins
Leptin Receptors
Adiposity
Body Composition
Cytomegalovirus
Hypoglycemic Agents
Weight Gain
Insulin Resistance
Color
Insulin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Metabolic effects of transgenic melanocyte-stimulating hormone overexpression in lean and obese mice. / Savontaus, Eriika; Breen, Tracy L.; Kim, Andrea; Yang, Lucy M.; Chua, Jr., Streamson C.; Wardlaw, Sharon L.

In: Endocrinology, Vol. 145, No. 8, 08.2004, p. 3881-3891.

Research output: Contribution to journalArticle

Savontaus, Eriika ; Breen, Tracy L. ; Kim, Andrea ; Yang, Lucy M. ; Chua, Jr., Streamson C. ; Wardlaw, Sharon L. / Metabolic effects of transgenic melanocyte-stimulating hormone overexpression in lean and obese mice. In: Endocrinology. 2004 ; Vol. 145, No. 8. pp. 3881-3891.
@article{bc1ad9d366f54fa0b0cc7f5af7ceecfb,
title = "Metabolic effects of transgenic melanocyte-stimulating hormone overexpression in lean and obese mice",
abstract = "The proopiomelanocortin-derived peptide, α-MSH, inhibits feeding via melanocortin receptors in the hypothalamus and genetic defects inactivating the melanocortin system have been shown to lead to obesity in experimental animals and humans. To determine whether long-term melanocortinergic activation has significant effects on body weight and composition and insulin sensitivity, transgenic mice overexpressing N-terminal proopiomelanocortin, including α- and γ3-MSH, under the control of the cytomegalovirus-promoter were generated. The transgene was expressed in multiple tissues including the hypothalamus, in which both α-MSH and γ3-MSH levels were increased approximately 2-fold, compared with wild-type controls. Transgene homozygous mice were also crossed with obese leptin receptor-deficient db3J and obese yellow Ay mice. MSH overespression led to uniform, dose-dependent darkening of coat color. MSH overexpression reduced weight gain and adiposity and improved glucose tolerance in lean male mice. In female transgenic mice, there was no significant effect on body weight, but there was a significant decrease in insulin levels. Obesity was attenuated in obese db3Jldb3J male and female mice, but there was no improvement in glucose metabolism. In contrast, the MSH transgene improved glucose tolerance in male Ay mice. These results support the hypothesis that long-term melanocortinergic activation could serve as a potential strategy for anti-obesity and/or antidiabetic therapy.",
author = "Eriika Savontaus and Breen, {Tracy L.} and Andrea Kim and Yang, {Lucy M.} and {Chua, Jr.}, {Streamson C.} and Wardlaw, {Sharon L.}",
year = "2004",
month = "8",
doi = "10.1210/en.2004-0263",
language = "English (US)",
volume = "145",
pages = "3881--3891",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Metabolic effects of transgenic melanocyte-stimulating hormone overexpression in lean and obese mice

AU - Savontaus, Eriika

AU - Breen, Tracy L.

AU - Kim, Andrea

AU - Yang, Lucy M.

AU - Chua, Jr., Streamson C.

AU - Wardlaw, Sharon L.

PY - 2004/8

Y1 - 2004/8

N2 - The proopiomelanocortin-derived peptide, α-MSH, inhibits feeding via melanocortin receptors in the hypothalamus and genetic defects inactivating the melanocortin system have been shown to lead to obesity in experimental animals and humans. To determine whether long-term melanocortinergic activation has significant effects on body weight and composition and insulin sensitivity, transgenic mice overexpressing N-terminal proopiomelanocortin, including α- and γ3-MSH, under the control of the cytomegalovirus-promoter were generated. The transgene was expressed in multiple tissues including the hypothalamus, in which both α-MSH and γ3-MSH levels were increased approximately 2-fold, compared with wild-type controls. Transgene homozygous mice were also crossed with obese leptin receptor-deficient db3J and obese yellow Ay mice. MSH overespression led to uniform, dose-dependent darkening of coat color. MSH overexpression reduced weight gain and adiposity and improved glucose tolerance in lean male mice. In female transgenic mice, there was no significant effect on body weight, but there was a significant decrease in insulin levels. Obesity was attenuated in obese db3Jldb3J male and female mice, but there was no improvement in glucose metabolism. In contrast, the MSH transgene improved glucose tolerance in male Ay mice. These results support the hypothesis that long-term melanocortinergic activation could serve as a potential strategy for anti-obesity and/or antidiabetic therapy.

AB - The proopiomelanocortin-derived peptide, α-MSH, inhibits feeding via melanocortin receptors in the hypothalamus and genetic defects inactivating the melanocortin system have been shown to lead to obesity in experimental animals and humans. To determine whether long-term melanocortinergic activation has significant effects on body weight and composition and insulin sensitivity, transgenic mice overexpressing N-terminal proopiomelanocortin, including α- and γ3-MSH, under the control of the cytomegalovirus-promoter were generated. The transgene was expressed in multiple tissues including the hypothalamus, in which both α-MSH and γ3-MSH levels were increased approximately 2-fold, compared with wild-type controls. Transgene homozygous mice were also crossed with obese leptin receptor-deficient db3J and obese yellow Ay mice. MSH overespression led to uniform, dose-dependent darkening of coat color. MSH overexpression reduced weight gain and adiposity and improved glucose tolerance in lean male mice. In female transgenic mice, there was no significant effect on body weight, but there was a significant decrease in insulin levels. Obesity was attenuated in obese db3Jldb3J male and female mice, but there was no improvement in glucose metabolism. In contrast, the MSH transgene improved glucose tolerance in male Ay mice. These results support the hypothesis that long-term melanocortinergic activation could serve as a potential strategy for anti-obesity and/or antidiabetic therapy.

UR - http://www.scopus.com/inward/record.url?scp=3843114437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3843114437&partnerID=8YFLogxK

U2 - 10.1210/en.2004-0263

DO - 10.1210/en.2004-0263

M3 - Article

C2 - 15117873

AN - SCOPUS:3843114437

VL - 145

SP - 3881

EP - 3891

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 8

ER -